Navigation Links
UCLA scientists find molecular switch to prevent Huntington's disease in mice
Date:12/24/2009

UCLA scientists have identified a molecular switch that prevents Huntington's disease from developing in mice. Published in the Dec. 24 edition of the journal Neuron, the discovery suggests a new approach to treating the genetic disorder, which ultimately leads to death in as little as 10 years.

Affecting one out of every 10,000 Americans, Huntington's progressively deprives patients of their ability to walk, speak, think clearly and swallow. People who inherit the disorder don't show symptoms until mid-life, after many have had children and unknowingly passed on the disease. Currently, there is no effective treatment to prevent the onset or slow the progression of the disease.

Huntington's is caused by a mutation in the polyglutamine (polyQ) region of a very large protein called huntingtin. Because huntingtin is found everywhere in the body, it is a challenge to study, and the function and mechanism behind the mutant protein still remain elusive.

"It's unclear how the mutant protein causes age-related and progressive loss of brain cells in patients with Huntington's disease," said senior study author X. William Yang, associate professor of psychiatry and biobehavioral sciences at the Semel Institute of Neuroscience and Human Behavior at UCLA. "We explored whether regions of the protein besides the polyQ mutation play a role in the development of the disorder."

Collaborators Joan Steffan and Leslie Thompson, of the University of California, Irvine, showed that two amino acids near the beginning of the huntingtin protein can be modified by a chemical process called phosphorylation, which cells use to control protein function after the proteins have been made.

To test whether phosphorylation could influence Huntington's disease in a living animal, Yang's laboratory generated two mouse models to carry the polyQ HD mutation and modified the two amino acids in two different ways one to mimic phosphorylation, the other to prevent it.

The researchers found that preventing phosphorylation caused the mice to develop symptoms suggestive of Huntington's disease in humans. Mimicking phosphorylation, however, did not cause the disorder.

These results in mice have striking parallels to experiments performed by collaborator Ron Wetzel, of the University of Pittsburgh, who found that mimicking phosphorylation of a toxic fragment of mutant huntingtin reduces the protein's tendency to form clumps.

A separate UC Irvine study by Steffan and Thompson also suggests that phosphorylation of mutant huntingtin may help cells dispose of the toxic form of mutant huntingtin. Combined, these studies suggest new directions of research to understand the roles of huntingtin misfolding, clumping and clearance in the disease mechanism.

"Our study identified a critical molecular switch which lies next to the polyQ mutation in the huntingtin protein," Yang said. "We were surprised to find that subtle modification of only two amino acids in this very large protein can prevent the onset of disease. This finding suggests an exciting new avenue to develop therapeutics for Huntington's disease."


'/>"/>

Contact: Elaine Schmidt Haber
ehaber@mednet.ucla.edu
310-794-2272
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. Turtles Christmas journey tracked by scientists
2. Scientists isolate new antifreeze molecule in Alaska beetle
3. Scientists use nanosensors for first time to measure cancer biomarkers in blood
4. Scripps Research scientists crack mystery of proteins dual function
5. Scientists identify natural anti-cancer defenses
6. Princeton scientists find way to catalog all that goes wrong in a cancer cell
7. The pitch of blue whale songs is declining around the world, scientists discover
8. Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists
9. Scientists discover gene module underlying atherosclerosis development
10. Scientists think killer petunias should join the ranks of carnivorous plants
11. Scientists gain new understanding of disease-causing bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... 2016 , ... DrugDev believes the only way to achieve real ... All three tenets were on display at the 2nd Annual DrugDev User Summit (hosted ... CRO and site organizations to discuss innovation and the future of clinical research. ...
(Date:12/2/2016)... 2, 2016 The immunohistochemistry (IHC) market ... a CAGR of 7.3% during the forecast period of 2016 to ... laboratories segment accounted for the largest share of immunohistochemistry (IHC) market, ... , ... immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies and ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
Breaking Biology Technology: